These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 1496919)

  • 1. Factors affecting the mRNA levels for the non-heme iron and effector-binding subunits of ribonucleotide reductase.
    Carter GL; Cory JG
    Adv Enzyme Regul; 1992; 32():227-40. PubMed ID: 1496919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell-cycle associated transcriptional regulation of ribonucleotide reductase in L1210 leukemia cells and drug-resistant variants.
    Johnson CE; Hughes K; Cory JG
    Cancer Commun; 1991; 3(10-11):341-9. PubMed ID: 1760249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of drug resistance to inhibitors directed at the individual subunits of ribonucleotide reductase.
    Carter GL; Thompson DP; Cory JG
    Cancer Commun; 1989; 1(1):13-20. PubMed ID: 2701080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The utility of combinations of drugs directed at specific sites of the same target enzyme--ribonucleotide reductase as the model.
    Cory JG; Sato A; Carter GL; Bacon PE; Montgomery JA; Brown NC
    Adv Enzyme Regul; 1985; 23():181-92. PubMed ID: 3907303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo growth of mouse leukemia L1210 cells with metabolic alterations in the subunits of ribonucleotide reductase.
    Somerville L; Cory AH; Cory JG
    In Vivo; 2002; 16(3):175-7. PubMed ID: 12182112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in messenger RNA levels for the subunits of ribonucleotide reductase during the cell cycle of leukemia L1210 cells.
    Thompson DP; Carter GL; Cory JG
    Cancer Commun; 1989; 1(4):253-60. PubMed ID: 2700914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential turnover of the subunits of ribonucleotide reductase in synchronized leukemia L1210 cells.
    Rubin EH; Cory JG
    Cancer Res; 1986 Dec; 46(12 Pt 1):6165-8. PubMed ID: 3536076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
    Cory AH; Sato A; Thompson DP; Cory JG
    Oncol Res; 1996; 8(10-11):449-56. PubMed ID: 9114437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells.
    Carter GL; Cory JG
    Cancer Res; 1988 Oct; 48(20):5796-9. PubMed ID: 2844392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the differential mechanisms of inhibition of ribonucleotide reductase by specific inhibitors of the non-heme iron subunit.
    Sato A; Bacon PE; Cory JG
    Adv Enzyme Regul; 1984; 22():231-41. PubMed ID: 6089512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of biochemical modulation of drug combinations directed at the ribonucleotide reductase site on leukemia L1210 cell growth in culture.
    Sato A; Carter GL; Bacon PE; Cory JG
    Adv Enzyme Regul; 1983; 21():259-70. PubMed ID: 6400064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of combinations of drugs having different modes of action at the ribonucleotide reductase site on growth of L1210 cells in culture.
    Sato A; Carter GL; Bacon PE; Cory JG
    Cancer Res; 1982 Nov; 42(11):4353-7. PubMed ID: 6751522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug action on ribonucleotide reductase.
    Cory JG; Carter GL
    Adv Enzyme Regul; 1985; 24():385-401. PubMed ID: 3915189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective resistance of L1210 cell lines to inhibitors directed at the subunits of ribonucleotide reductase.
    Carter GL; Cory JG
    Adv Enzyme Regul; 1989; 29():123-39. PubMed ID: 2699151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered steady-state levels of the messenger RNAs for c-myc and p53 in L1210 cell lines resistant to deoxyadenosine.
    Cory JG; Cory AH; Long SD; Carter GL; Johnson CE
    Cancer Res; 1992 Apr; 52(7):2000-3. PubMed ID: 1551129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2'-Deoxy-2'-methylene derivatives of adenosine, guanosine, tubercidin, cytidine and uridine as inhibitors of L1210 cell growth in culture.
    Cory AH; Samano V; Robins MJ; Cory JG
    Biochem Pharmacol; 1994 Jan; 47(2):365-71. PubMed ID: 8304981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination chemotherapy directed at the components of nucleoside diphosphate reductase.
    Cory JG; Chiba P
    Pharmacol Ther; 1985; 29(1):111-27. PubMed ID: 3914643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms responsible for the drug-induced posttranscriptional modulation of ribonucleotide reductase levels in a hydroxyurea-resistant mouse L cell line.
    McClarty GA; Chan AK; Choy BK; Thelander L; Wright JA
    Biochemistry; 1988 Sep; 27(19):7524-31. PubMed ID: 3061459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribonucleotide reductase activity and growth of glutathione-depleted mouse leukemia L1210 cells in vitro.
    Weckbecker G; Cory JG
    Cancer Lett; 1988 Jun; 40(3):257-64. PubMed ID: 3289734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in the components of ribonucleotide reductase in hydroxyurea-resistant hamster cells.
    Wright JA; Cory JG
    Biosci Rep; 1983 Aug; 3(8):741-8. PubMed ID: 6354297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.